Loading...

Roche Holding AG

RHHBY•PNK
Healthcare
Drug Manufacturers - General
$39.64
$-0.64(-1.59%)

Roche Holding AG (RHHBY) Stock Overview

Explore Roche Holding AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap257.1B
P/E Ratio19.16
EPS (TTM)$1.62
ROE0.35%
Fundamental Analysis

AI Price Forecasts

1 Week$41.28
1 Month$43.16
3 Months$45.61
1 Year Target$40.30

RHHBY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Roche Holding AG (RHHBY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.85, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $40.30.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 19.16 and a market capitalization of 257.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

43.85RSI (14)
0.04MACD
10.27ADX
Stats data is not available for RHHBYStats details for RHHBY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
1
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

CEO

Thomas Schinecker

Employees

103,249

Headquarters

Konzern Hauptsitz, Basel

Founded

2003

Frequently Asked Questions

;